NCT06327269View on ClinicalTrials.gov

Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2026

Conditions
High Risk of Recurrence
Interventions
DRUG

Lenvatinib 10 mg

Lenvatinib would be used on patients with advanced liver cancer after Liver transplantation as an adjuvant treatment.

Trial Locations (1)

833

RECRUITING

Department of Surgery, Kaohsiung City

All Listed Sponsors
collaborator

Ministry of Health and Welfare, Taiwan

OTHER_GOV

lead

Chang Gung Memorial Hospital

OTHER